Curaleaf vs. Aurora: The $4 Cannabis Takeover Fight Gets Hostile — Literally

On Monday, the hostile takeover battle between Curaleaf Holdings (TSX: CURA, OTCQX: CURLF) and Aurora Cannabis (NASDAQ/TSX: ACB) escalated into a public dispute over the underlying economics of the deal. Aurora accused Curaleaf of using inaccurate and outdated information to portray its international cannabis business as underperforming; hours later, Curaleaf fired back, defending its analysis and arguing that Aurora’s management is selectively presenting data while failing to address years of shareholder underperformance.

For investors, the exchange matters beyond the increasingly combative language. Both companies are now publicly debating the assumptions that determine what Aurora is actually worth: cultivation productivity, international growth, Germany, margins and management’s ability to create value independently. Those questions ultimately determine whether Curaleaf’s offer represents an attractive premium or an attempt to acquire Aurora’s international infrastructure before its turnaround is fully reflected in the share price.

How We Got Here

Curaleaf first announced its intention to acquire Aurora on Aug. 11 after private approaches dated June 23 and July 7 failed to produce an agreement. Aurora responded by establishing a special committee and telling shareholders to take no action. Curaleaf subsequently bypassed the board and formally launched its offer directly to shareholders.

The offer provides Aurora shareholders with $0.75 in cash plus 0.3463 Curaleaf shares for each Aurora share, implying $4 per share based on Curaleaf’s Aug. 10 price. Curaleaf characterized that as a 45% premium to Aurora’s unaffected share price, although the ultimate value of the stock component moves with Curaleaf shares and is subject to a $5 cap.

Curaleaf’s last major move before Monday’s exchange was therefore not another proposal to Aurora’s board: it was the formal tender offer asking Aurora shareholders themselves to decide. The offer remains open until Dec. 1 unless extended.

Aurora Challenges Curaleaf’s Math

Aurora’s Monday response attacks the assumptions Curaleaf is using to justify the acquisition.

Aurora said its international net revenue increased 17% year over year and rejected Curaleaf’s characterization of Germany, arguing that its high-margin German operation continues to grow.

CEO Miguel Martin described the bid as opportunistic, arriving as Aurora reaches what he called a “pivotal inflection point” following three consecutive years of positive adjusted EBITDA and expanding international sales.

Importantly, Aurora also challenged Curaleaf’s characterization of its cultivation performance — an issue Boris Jordan discussed extensively in an exclusive interview with IgniteIt.

Aurora argues that Curaleaf is relying on information that does not adequately capture improvements in its production platform.

That dispute goes directly to the economics of the transaction. If Aurora can materially increase output from existing EU-GMP infrastructure while international sales expand, Curaleaf could be acquiring operating leverage that has not yet appeared fully in Aurora’s earnings.

Curaleaf Fires Back

Curaleaf responded the same day and essentially argued: show shareholders the numbers.

The company said its cultivation comparison uses Aurora’s own latest audited fiscal 2026 disclosures, including Aurora’s reported 114 grams per plant, and claimed Curaleaf’s yields are more than twice that level.

Curaleaf challenged Aurora to disclose better information if management believes those figures no longer represent the business.

Curaleaf also rejected Aurora’s characterization of negotiations, maintaining that the companies have not had a substantive transaction discussion and pointing to Aurora’s unwillingness to enter an NDA or permit a site visit.

For investors, neither press release settles the valuation question. Curaleaf benefits from portraying Aurora as an underutilized asset that its operating platform can improve. Aurora benefits from arguing that Curaleaf is attempting to purchase the company just as years of restructuring are beginning to produce results.

But $4 represents a premium to what?

Three Questions Investors Should Be Asking

1. What is Aurora worth if management is right about the inflection point?
Investors need a standalone valuation incorporating international revenue growth, Germany, UK expansion, and potential operating leverage, and then compare that value with Curaleaf’s offer, rather than simply comparing $4 with Aurora’s pre-bid share price.

2. Who can prove the cultivation economics?
Curaleaf is pointing to Aurora’s audited disclosures; Aurora says Curaleaf’s characterization is outdated. Yield alone is insufficient. Investors need comparable data on yield, cost per gram, selling price, utilization, and margins to determine whether Curaleaf’s claimed operational upside is real.

3. How much of the proposed combination’s value would Aurora shareholders actually capture?
If Curaleaf can generate roughly $40 million in synergies and materially improve Aurora’s international assets, shareholders should ask how much of that value is already reflected in the consideration and how much Curaleaf is attempting to retain for its own shareholders.